1. UNAIDS, 2019. Global HIV & AIDS statistics. http://www.unaids.org/en/resources/factsheet. 2. Burton DR, Mascola JR. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol. 2015; 16(6): 571-576. 3. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol. 2001; 19: 1173-1176. 4. Bolhassani A, Jafarzade BS, Mardani G. In vitro and in vivo delivery of therapeutic proteins usingcell penetrating peptides. Pept. 2016; 16: 1-46. 5. Lee JE, Lim HJ. LDP12, a novel cell-permeable peptide derived from L1 capsid protein of the human papillomavirus. Mol Biol Rep. 2012; 39:1079–1086. 6. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target Sci. 2009; 326 (5950): 285-9. 7. Lai RPJ, Yan J, Heeney J, McClure MO, Go¨ ttlinger H, Luban J, et al. Nef Decreases HIV-1 Sensitivity to Neutralizing Antibodies that Target the Membrane-proximal External Region of TMgp41. PLoS Pathog. 2011; 7(12): 1-15. 8. Garcia JV, Miller AD. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nat. 1991; 350: 508-511. 9. Aiken C, Konner J, Landau NR, Lenburg ME, Trono D. Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membraneproximal CD4 cytoplasmic domain. Cell. 1994; 76(5): 853-864. 10. Piguet V, Gu F, Foti M, Demaurex N, Gruenberg J, Carpentier JL, el al. Nef-induced CD4 degradation: a diacidic-based motif in Nef functions as a lysosomal targeting signal through the binding of beta-COP in endosomes. Cell. 1999; 97(1): 63-73. 11. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med. 1996; 2(3): 338-342. 12. Blagoveshchenskaya AD, Thomas L, Feliciangeli SF, Hung CH, Thomas G. HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway. Cell. 2002; 111(6): 853-866. 13. Baur AS, Sawai ET, Dazin P, Fantl WJ, Cheng-Mayer C, Peterlin BM. HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization. Immunity. 1994; 1(5): 373-384. 14. Schrager JA, Marsh JW. HIV-1 Nef increases T cell activation in astimulus-dependent manner. Proc Natl Acad Sci U S A. 1999; 96(14): 8167-8172. 15. Alexander L, Du Z, Rosenzweig M, Jung JU, Desrosiers RC. A role for natural simian immunodeficiency virus and human immunodeficiency virus type1 nef alleles in lymphocyte activation. J Virol. 1997; 71(8): 6094-6099. 16. Simmons A, Aluvihare V, McMichael A. Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. Immunity. 2001; 14(6): 763-777. 17. Foster JL, Garcia JV. HIV-1 Nef: at the crossroads. Retrovirology. 2008 :84(5):1-13. 18. Geyer M, Fackler OT, Peterlin BM. Structure-function relationships in HIV-1 Nef. EMBO Rep. 2001; 2(7): 580-85. 19. Laguette, N. Bregnard, Ch. Benichou, S. Basmaciogullari, S. Human immunodeficiency virus (HIV) type-1, HIV-2 and simian immunodeficiency virus Nef proteins. Mol aspects Med. 2010; 31(5):418-433. 20. Lindwasser, OW. Chaudhuri, R. Bonifacino, JS. Mechanisms of CD4 downrwgulation by the Nef and Vpu proteins of primate immunodeficiency viruses. Curr Mol Med. 2007; 7(2):171-184. 21. Visciano ML, Diomede L, Tagliamonte M, Tornesello ML, Asti V, Bomsel M, et al. Generation of HIV-1 virus-like particles expressing different HIV-1 glycoproteins. Vaccine. 2011; 29(31): 4903-12. 22. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target Sci. 2009; 326 (5950): 285-9. 23. Gorny MK, Williams C, Volsky B, Revesz K, Wang XH, Burda S, et al. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. J. Virol. 2006; 80 (14):6865–72. 24. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One. 2010; 5(1): e8805. 25. Montero M, Houten NEV, Wang X, Scott JK. The Membrane-Proximal External Region of the Human Immunodeficiency Virus Type 1 Envelope: Dominant Site of Antibody Neutralization and Target for Vaccine Design. Microbiol Mol Biol Rev. 2008; 72(1): 54-84. 26. Munoz-Barroso I, Salzwedel K, Hunter E, Blumenthal R. Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J. Virol. 1999; 73(7): 6089-6092. 27. Salzwedel K, West JT, Hunter E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J. Virol. 1999; 73(3): 2469-2480. 28. Sirois, S. Sing, T. Chou, KC. HIV-1 gp120 V3 loop for structure-based drug design. Curr Protein Pept Sc. 2005; 6(5): 413-422. 29. M.Andrianov, A. V,Anishchenko, I. V.Tuzikov, A. Discovery of novel promising targets for anti-AIDS drug developments by computer modeling: application to the HIV-1 gh120 V3 loop. J. Chem. Inf. Model. 2011; 51(10):2760-67. 30. Zwick, MB. Jensen, R. Church, S. et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 2005; 79(2):1252-1261. 31. Zwick, MB. Labrijin, AF. Wang, M. et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 2001; 75(22):10892-10905. 32. Van Gils MJ, Sanders RW. Broadly neutralizing antibodies against HIV-1: Templates for a vaccine. Virology. 2013; 435(1):46-56. 33. Sabaghzadeh S, Sadat SM, Rohollah F, Bolhassani A. Effective delivery of Nef-MPER-V3 fusion protein using LDP12 cell penetrating peptide for development of preventive/therapeutic HIV-1 vaccine. Protein Peptide Lett. 2020 May 4. doi: 10.2174/092986652766620050412140. 34. Faghih A, Sadat SM, Bolhassani A, Irani SH. Cloning, Optimization of Expression Condition and Purification of the Recombinant HIV-1 Nef- MPER-V3 Protein in Prokaryotic Expression System. Pars J. Med. Sci.2019;17(2):46-53. 35. Sadat SM, Zabihollahi R, Javadi F, Vahabpour R, Siadat SD, Azadmanesh K, et al. Immunological evaluation of recombinant HIV1 virions with novel adjuvants in BALB/c mice model. J Mazandaran Univ Med Sci. 2011; 21(84):13-21. 36. Gray EG, Laher F, Lazarus E, Ensoli B, Corey L. Approaches to preventative and therapeutic HIV vaccines. Curr Opin Virol. 2016; 17: 104-109. 37. Walker BD, Ahmed R, Plotkin S. Moving ahead an HIV vaccine: use both arms to beat HIV. Nat Med. 2011; 17: 1194-5. 38. Excler JL, Robb ML, Kim JH. Prospects for a globally effective HIV-1 vaccine. Vacc. 2015; 33: 1-9. 39. Tohidi F, Sadat SM, Bolhassani A, Yaghobi R. Immunological Evaluation of HIV-1 VLP Harboring MPER-V3 in BALB/c Mice Model. Patho Res. 2018; 21(2): 95-100. 40. Guo Z, Peng H, Kang J, Sun D. Cell-penetrating peptides: Possible transduction mechanisms and therapeutic applications. Biomed Rep. 2016; 4(5): 528-34. 41. Kwon S, Kwak A, Shin H, Choi S, Kim S, Lim HJ. Application of a novel cell-permeable peptide-driven protein delivery in mouse blastocysts. Reproduction. 2013; 146: 145-153. 42. Reguzova A, Antonets D, Karpenko L, Ilyichev A, Maksyutov R, Bazhan S. Design and evaluation of optimized artificial HIV-1 Poly-T cell-epitope immunogens. PloS One. 2015; 10(3): e0116412. 43. Haynes BF, Montefiori DC. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines. 2006; 5(4): 579-95. 44. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med. 2007; 13(9): 1032-1034. 45. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat Med. 2009; 15(8): 866-70. 46. Fomsgaard A, Nielsen HV, Bryder K, Nielsen C, Machuka R, Bruun L, et al. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the Hepatitis B surface antigen. Scand. J. Immunol. 1998; 47: 289-295. 47. Sirois S, Touaibia M, Chou KC, Roy R. Glycosylation of HIV-1 gp120 V3 Loop: Towards the Rational Design of a Synthetic Carbohydrate Vaccine. Curr. Med. Chem. 2007; 14: 3232-3242. 48. Kestler HWd, Ringler DJ, Mori K, et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell. 1991; 65(4): 651–62. 49. Svanholm C, Lowenadler B, Wigzell H. Amplification of T-cell and antibody responses in DNA-based immunization with HIV-1 Nef by co-injection with a GM-CSF expression vector. Scand. J. Immunol. 1997; 46: 298-303. 50. Cosma A, Nagaraj R, Bühler S, Hinkula J, Busch DH, Sutter G, et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vacc. 2003; 22: 21-29.
مجله علوم پزشکی پارس
)